Dr. David H. Donabedian is an Executive Partner at Longwood Fund. He joined the fund in 2015 as a Venture Partner and has over 20 years of professional experience and expertise leading business development, venture teams and demonstrated track record of company creation. He is co-founder and start-up CEO of DEM BioPharma, start-up CEO of Longwood-founded ImmuneID, founding CEO of Longwood-founded Axial Therapeutics and founding executive of Alcyone Therapeutics.

Prior to joining Longwood, Dr. Donabedian held various leadership roles at biopharmaceutical companies including AbbVie (NASDAQ: ABBV) and GlaxoSmithKline (NYSE: GSK). At AbbVie he served as Vice President and Global Head of Ventures and Early-Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President of Global New Deal Strategy and Development at GlaxoSmithKline, VP of Business Development, Surface Logix, (sold to Kadmon, acquired by Sanofi, for $1.9B) and Senior Manager at Accenture's Strategic Services Consulting Group.

Dr. Donabedian holds a B.A. in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Anuncia Inc. and Alcyone Therapeutics, Inc.